[Witt, Olaf, Deubzer, Hedwig Elisabeth, Westermann, Frank, Roenndahl, Gabi, Heinrich, Ralf, Ehemann, Volker] Im Neuenheimer Feld 280, 69120 Heidelberg, DE The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases.

[HIRT WERNER DR, EHEMANN VOLKER DR, WINK ALEXANDER] DE The invention concerns a process for determining the effect of effectors on target cells, characterized in that, as target cells, thawed cryopreserved mammalian cells are used which have not previously been cultivated and, after storage at -70 DEG C for a period of 4 weeks, have at least 85 % vitality. These cells are obtained by preparing a suspension of the target cells in a medium, adding a cryopreservation agent up to a final concentration of 2 to 10 % (v/v) and freezing the cells at a temperature decrease of not more than 2 DEG C per minute.

[BRAUN, Klaus, WALDECK, Waldemar, PIPKORN, Rüdiger, BRAUN, Isabell, DEBUS, Jürgen, WOLBER, Gerd, EHEMANN, Volker] Im Neuenheimer Feld 280 69120 Heidelberg;Bruchhausen 1B 69207 Sandhausen;Tilsiter Strasse 49 69514 Laudenbach;Adolf-Rauch-Strasse 3 69120 Heidelberg;Höhenweg 13 35091 Cölbe-Bürgeln;Kreuzstrasse 11 76698 Stettfeld;Mozartstrasse 27 69198 Schriesheim;Hans-Thoma-Strasse 23 69190 Walldorf The invention concerns conjugates comprising the following individual elements: (a) a transport mediator for the cell membrane; (b) an addressing protein or peptide for import into the cell nucleus; and (c) the boron-10 derivative to be transported. The invention also concerns the use of said conjugates for treating glioblastoma by boron neutron capture therapy (BNCT). Preferably, a cleavable covalent disulphide bond links (a) and (b).

[BRAUN, Klaus, BOCK, Michael, PIPKORN, Rüdiger, WALDECK, Waldemar, WIEßLER, Manfred, DIDINGER, Bernd, DEBUS, Jürgen, EHEMANN, Volker, DUNSCH, Lothar] Helmholtzstraße 20 01069 Dresden;Eichendorffstr. 9 69207 Sandhausen;Im Neuenheimer Feld 280 69120 Heidelberg;Adolf-Rausch-Str. 3 69124 Heidelberg;Tilsiterstr. 49 69514 Laudenbach;Wilhelm-Mayer-Str. 2 67227 Flomersheim;Gülserstr. 50 56073 Koblenz;Im Langewann 125 69121 Heidelberg;Stranggasse 28 69207 Sandhausen;Voglerstr. 23 01277 Dresden The invention relates to the areas of the materials sciences and to medicine, and relates to an agent that can be used as a contrast medium for the localization of cancer cells, for example. The object of the present invention is to provide an agent which sensitively and selectively recognizes the location and type of molecules or cells to be examined. The object is accomplished through an agent comprising at least bio-shuttle molecules to which endohedral fullerenes are coupled by way of peptide-based molecules, wherein the endohedral fullerenes are hydrophobic and correspond to the formula: A3-χMxZ@C2n, where x = 0 to 3, n ≥ 34, A is a rare earth and/or a transuranic element, M is a metal, Z is a non-metal and C is carbon. The object is further accomplished through a method in which hydrophobic, endohedral fullerenes are coupled to bio-shuttle molecules by way of an irreversible Diels-Alder reaction that has an inverse electron demand (DARιnv).

[WITT, Olaf, DEUBZER, Hedwig Elisabeth, WESTERMANN, Frank, ROENNDAHL, Gabi, HEINRICH, Ralf, EHEMANN, Volker] STIFTUNG DES OEFFENTLICHEN RECHTS Im Neuenheimer Feld 280 69120 Heidelberg;Grabengasse 1 69117 Heidelberg;Mannheimer Strasse 8 69198 Schriesheim;Steckelsgasse 21 69121 Heidelberg;Im Frauenpfad 19 69221 Dossenheim;Gertrudstrasse 5 32427 Minden;Pfaffenstueck 3 37077 Göttingen;Hans-thoma-strasse 23 691290 Waldorf The present invention relates to uses of compounds having a structure as shown by formula (I) for the manufacture of a pharmaceutical composition for the treatment of neuroblastoma. Moreover, the present invention encompasses methods of treatment for said diseases.

[BRAUN KLAUS, BOCK MICHAEL, PIPKORN RUEDIGER, WALDECK WALDEMAR, WIESLER MANFRED, DIDINGER BERND, DEBUS JUERGEN, EHEMANN VOLKER, DUNSCH LOTHAR] DE

[HIRT, Werner, EHEMANN, Volker, WINK, Alexander] Czerny-Ring 22, 69115 Heidelberg, DE

[EHEMANN VOLKER] DE

[HIRT WERNER, EHEMANN VOLKER, WINK ALEXANDER]

[DEUBZER, Hedwig, WITT, Olaf, WESTERMANN, Frank, BECKER, Gabriele, EHEMANN, Volker, ROENNDAHL, Gabi, HEINRICH, Ralf] Im Neuenheimer Feld 280 69120 Heidelberg;Grabengasse 1 69117 Heidelberg;Steckelsgasse 21 69121 Heidelberg;Mannheimer Strasse 8 69198 Schriesheim;Frauenpfad 19 69221 Dossenheim;Cranachstrasse 10 69257 Wiesenbach;Hans-Thomastrasse 23 69190 Walldorf;Gertrudstrasse 5 32427 Minden;Pfaffenstueck 3 37077 Göttingen The present invention relates to treating a subject who has a small round blue cell tumor with a histone deacetylase inhibitor, particularly with an inhibitor that is Helminthosporium Carbonum toxin. Helminthosporium carbonum toxin reverses in nano mo lar dosage tumor cells from malignant towards benign. Conversion to benign is associated with activation of retinoblastoma tumor suppression networks. Stimulating tumor suppression pathways presents a novel approach to small round blue cell tumor therapy.